VPC
VTYX

Vestal Point Capital’s Ventyx Biosciences VTYX Stock Holding History

Vestal Point Capital’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,050,000
Closed -$6.38M – 103
2025
Q3 		$6.38M Buy
2,050,000
+50,000
+3% +$132K 0.29% 59
2025
Q2 		$4.28M Hold
2,000,000
– – 0.23% 56
2025
Q1 		$2.3M Hold
2,000,000
– – 0.16% 51
2024
Q4 		$4.38M Buy
2,000,000
+275,000
+16% +$623K 0.26% 56
2024
Q3 		$3.76M Buy
1,725,000
+410,000
+31% +$943K 0.29% 54
2024
Q2 		$3.04M Buy
+1,315,000
New +$5.46M 0.23% 51

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vestal Point Capital's VTYX Position: Q4 2025 in Review

Vestal Point Capital sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 2,050,000 shares — an estimated $6.38M sold.

Vestal Point Capital first reported a position in VTYX in Q2 2024 and held it in 6 quarters. The position peaked at $6.38M in Q3 2025. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Vestal Point Capital reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Vestal Point Capital sold 2,050,000 Ventyx Biosciences shares in Q4 2025, an estimated $6.38M.
  • Vestal Point Capital first reported a position in Ventyx Biosciences in Q2 2024 and held it in 6 quarters.
  • Vestal Point Capital's Ventyx Biosciences position peaked at $6.38M in Q3 2025.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.